Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Elisa Kiselev und 36 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Benzylamines. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ERC Advanced, SFB1470, Förderstiftung MHH.
Abstract (Originalsprache)
Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood. In this study we investigate the effects of MAVA across diverse cardiac models, including healthy female porcine cardiomyocytes and myocardial slices, human induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs), cardiac organoids and living myocardial slices (LMSs) derived from patients with HOCM. Experimental Approach Long‐term LMS culture facilitated continuous force measurements, while SarcTrack and MUSCLEMOTION analyses were used to evaluate contractility in cardiomyocytes and cardiac organoids. Transcriptome profiling of MAVA‐treated HOCM hiPSC‐CMs and HOCM LMSs allowed in‐depth examination of gene expression signatures in response to MAVA treatment. Key Results Across all models tested, MAVA demonstrated robust force inhibition. In primary disease models, MAVA showed little effect on time to peak or relaxation times and even reduced contraction and relaxation velocities. By contrast, in engineered human HOCM models, MAVA accelerated both contraction and relaxation, suggesting potential model‐specific effects. Transcriptome analyses revealed that MAVA treatment not only influenced contraction regulation but also significantly altered cytoskeleton organization, muscle stretch response, and metabolic pathways. Notably, in LMSs derived from three HOCM patients, MAVA treatment up‐regulated myosin binding protein H ( MyBPH ) expression, suggesting that MyBPH may also be involved in contraction regulation. Conclusion and Implications These data suggest that MAVA not only inhibits force within the sarcomere but also influences transcriptional pathways in model‐specific manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.
- Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
- Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
- Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
- Department of General, Visceral, Pediatric and Transplantation Surgery, University Hospital RWTH Aachen, Aachen, Germany.
- Lower Saxony Center for Biomedical Engineering, Implant Research and Development, Hannover Medical School, Hannover, Germany.
Förderung
- ERC Advanced
- SFB1470
- Förderstiftung MHH
- German Society of Cardiology Grant (DGK Forschungsstipendium)
- Else Kröner-Fresenius Foundation
- Hannover Medical School
- German Research Foundation
- Wellcome Sir Henry Dale Fellowship
Zitieren
APA
Kiselev, E., Agyapong, W., Jürgens, B., Mohr, E., Chatterjee, S., Hunkler, H. J., Salman, J., Cipriano, G., Bentele, M., Liu, J., Specht, J., Menge, K. S., Waleczek, F. J. G., Haas, J. A., Derda, A. A., Sonnenschein, K., Gietz, A., Neumüller, S., Pfanne, A., …, & Thum, T. (2026). Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy. British Journal of Pharmacology. https://doi.org/10.1111/bph.70247
Vancouver
Kiselev E, Agyapong W, Jürgens B, Mohr E, Chatterjee S, Hunkler HJ, et al. Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy. British Journal of Pharmacology. 2026. doi:10.1111/bph.70247
BibTeX
@article{Kiselev2026,
author = {Kiselev, Elisa and Agyapong, Wilson and Jürgens, Bjarne and Mohr, Elisa and Chatterjee, Shambhabi and Hunkler, Hannah J and Salman, Jawad and Cipriano, Giuseppe and Bentele, Marco and Liu, Junqing and Specht, Jonas and Menge, Kaja S and Waleczek, Florian J G and Haas, Jonas A and Derda, Anselm A and Sonnenschein, Kristina and Gietz, Anika and Neumüller, Susanne and Pfanne, Angelika and Beetz, Oliver and Pflaum, Michael and Wiegmann, Bettina and Psaras, Yiangos and Toepfer, Christopher and Zweigerdt, Robert and Radocaj, Ante and Kraft, Theresia and Zeug, Andre and Ponimaskin, Evgeni and Korte, Wilhelm and Horke, Alexander and Ruhparwar, Arjang and Fuchs, Maximilian and Xiao, Ke and Bär, Christian and Weber, Natalie and Thum, Thomas},
title = {Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70247}
}
EUVIMED